Takeda Pharmaceutical Company Limited(TAK)Earnings, Financials & Key Ratios
TAK•NYSE
39.3× P/E·Price updated Jun 19, 2026
AboutTakeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.Show more
- Revenue$4777.45B+4.3%
- EBITDA$1337.66B+21.2%
- Net Income$203.33B+88.4%
- EPS (Diluted)63.91+90.1%
- Gross Margin51.06%-22.1%
- EBITDA Margin28%+16.2%
- Operating Margin11.99%+60.4%
- Net Margin4.26%+80.7%
- ROE2.76%+81.6%
TAK Key Insights
Takeda Pharmaceutical Company Limited (TAK) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 16.9% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Healthy dividend yield of 4.1%
- ✓Trading at only 1.0x book value
✗Weaknesses
- ✗Weak 3Y average ROE of 2.1%
- ✗Profits declining 11.6% over 5 years
- ✗Dividend payout exceeds 100% of earnings
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when TAK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
TAK Price & Volume
Takeda Pharmaceutical Company Limited (TAK) stock price & volume — 10-year historical chart
Loading chart...
TAK Growth Metrics
Takeda Pharmaceutical Company Limited (TAK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years10.21%
5 Years8.36%
3 Years5.86%
TTM-0.75%
Profit CAGR
10 Years9.75%
5 Years-11.57%
3 Years-13.76%
TTM79.07%
EPS CAGR
10 Years2.31%
5 Years-11.76%
3 Years-14.14%
TTM80.51%
Return on Capital
10 Years3.89%
5 Years3.54%
3 Years3.06%
Last Year4.62%
TAK Recent Earnings
Takeda Pharmaceutical Company Limited (TAK) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (64%)●Beat Revenue 8/12 qtrs (73%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.28+33.3%
$0.21
Rev
$6.9B-3.0%
$7.1B
Q1 2026
Jan 29, 2026Metric
Actual
Est
EPS
$0.48-12.7%
$0.55
Rev
$7.7B+2.5%
$7.5B
Q4 2025
Oct 30, 2025Metric
Actual
Est
EPS
$0.44+0.0%
$0.44
Rev
$7.4B-0.9%
$7.5B
Q3 2025
Jul 30, 2025Metric
Actual
Est
EPS
$0.52+10.6%
$0.47
Rev
$7.6B-3.9%
$8.0B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.28vs $0.21+33.3% | $6.9Bvs $7.1B-3.0% |
| Q1 2026 | Jan 29, 2026 | $0.48vs $0.55-12.7% | $7.7Bvs $7.5B+2.5% |
| Q4 2025 | Oct 30, 2025 | $0.44vs $0.44+0.0% | $7.4Bvs $7.5B-0.9% |
| Q3 2025 | Jul 30, 2025 | $0.52vs $0.47+10.6% | $7.6Bvs $8.0B-3.9% |
Based on last 12 quarters of dataView full earnings history →
TAK Peer Comparison
Takeda Pharmaceutical Company Limited (TAK) competitors in Therapy-focused branded biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NVO | 191.93B | 43.19 | 12.18 | 6.43% | 37.2% | 66.36% | 0.67 | |
 AZN | 271.19B | 174.93 | 26.75 | 8.63% | 17.19% | 22.24% | 0.61 | |
 SNY | 102.35B | 42.38 | 18.14 | 5.49% | 16.72% | 10.78% | 0.30 | |
 NVS | 280.64B | 147.08 | 20.46 | 5.97% | 24.14% | 31.42% | 0.80 | |
 GSK | 101.9B | 50.67 | 6.86 | 4.11% | 19.19% | 31.48% | 1.11 | |
 ABBV | 383.17B | 216.63 | 91.41 | 8.57% | 6.91% | 62.15% | ||
 BMY | 110.25B | 54.00 | 15.65 | -0.22% | 15.01% | 38.96% | 2.55 | |
 JNJ | 550.4B | 228.39 | 39.45 | 4.3% | 27.26% | 31.69% | 0.51 |
Compare TAK vs Peers
Takeda Pharmaceutical Company Limited (TAK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
TAK Income Statement
Takeda Pharmaceutical Company Limited (TAK) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 1.77T | 2.1T | 3.29T | 3.2T | 3.57T | 4.03T | 4.26T | 4.58T | 4.78T |
Revenue Growth % | 2.22% | 18.45% | 56.93% | -2.84% | 11.61% | 12.85% | 5.87% | 7.45% | 4.28% |
Cost of Goods Sold | 495.92B | 659.69B | 1.09T | 994.31B | 1.11T | 1.24T | 1.43T | 1.58T | 2.34T |
COGS % of Revenue | 28.01% | 31.46% | 33.11% | 31.09% | 31.01% | 30.89% | 33.57% | 34.49% | 48.94% |
Gross Profit | 1.27T▲ 0% | 1.44T▲ 12.8% | 2.2T▲ 53.1% | 2.2T▲ 0.1% | 2.46T▲ 11.7% | 2.78T▲ 13.0% | 2.83T▲ 1.8% | 3T▲ 6.0% | 2.44T▼ 18.7% |
Gross Margin % | 71.99% | 68.54% | 66.89% | 68.91% | 68.99% | 69.11% | 66.43% | 65.51% | 51.06% |
Gross Profit Growth % | 8.63% | 12.78% | 53.14% | 0.09% | 11.74% | 13.05% | 1.76% | 5.97% | -18.73% |
Operating Expenses | 1.03T | 1.28T | 2.1T | 1.69T | 2T | 2.29T | 2.62T | 2.66T | 1.87T |
OpEx % of Revenue | 58.33% | 60.9% | 63.84% | 52.98% | 56.07% | 56.93% | 61.41% | 58.03% | 39.06% |
Selling, General & Admin | 628.11B | 717.6B | 964.74B | 875.66B | 886.36B | 997.31B | 1.05T | 1.1T | 1.15T |
SG&A % of Revenue | 35.48% | 34.22% | 29.31% | 27.38% | 24.83% | 24.76% | 24.72% | 24.11% | 24.06% |
Research & Development | 325.44B | 368.3B | 492.38B | 455.83B | 526.09B | 633.33B | 729.92B | 730.23B | 716.69B |
R&D % of Revenue | 18.38% | 17.56% | 14.96% | 14.25% | 14.74% | 15.73% | 17.12% | 15.94% | 15% |
Other Operating Expenses | 707.38B | 908.87B | 643.9B | 362.74B | 588.87B | 662.27B | 834.44B | 823.75B | 0 |
Operating Income | 241.79B▲ 0% | 204.97B▼ 15.2% | 100.41B▼ 51.0% | 509.27B▲ 407.2% | 460.84B▼ 9.5% | 490.5B▲ 6.4% | 214.07B▼ 56.4% | 342.59B▲ 60.0% | 573.04B▲ 67.3% |
Operating Margin % | 13.66% | 9.77% | 3.05% | 15.93% | 12.91% | 12.18% | 5.02% | 7.48% | 11.99% |
Operating Income Growth % | 55.13% | -15.23% | -51.01% | 407.2% | -9.51% | 6.44% | -56.36% | 60.03% | 67.27% |
EBITDA | 423.92B | 452.66B | 684.06B | 1.07T | 1.04T | 1.15T | 858.54B | 1.1T | 1.34T |
EBITDA Margin % | 23.94% | 21.58% | 20.78% | 33.43% | 29.25% | 28.68% | 20.14% | 24.1% | 28% |
EBITDA Growth % | 29.52% | 6.78% | 51.12% | 56.26% | -2.33% | 10.62% | -25.66% | 28.59% | 21.17% |
D&A (Non-Cash Add-back) | 182.13B | 247.69B | 583.65B | 559.67B | 583.15B | 664.4B | 644.46B | 761.4B | 764.62B |
EBIT | 227.24B | 175.77B | 88.26B | 424.05B | 600.06B | 619.67B | 499.48B | 449.12B | 573.04B |
Net Interest Income | -6.78B | -60.96B | -1.36B | -128.65B | -117.67B | -111.19B | -984.34M | -117.67B | -155.22B |
Interest Income | 39.54B | 6.62B | 103.03M | 1.78B | 4.59B | 5.51B | 78.1M | 19.64B | 223.91B |
Interest Expense | 31.93B | 48.16B | 1.46B | 130.81B | 122.43B | 116.97B | 1.06B | 137.31B | 379.14B |
Other Income/Expense | -24.58B | -110.07B | -161.16B | -143.03B | -158.27B | -115.42B | -161.28B | -167.5B | -297.16B |
Pretax Income | 217.21B▲ 0% | 94.9B▼ 56.3% | -60.75B▼ 164.0% | 366.24B▲ 702.8% | 302.57B▼ 17.4% | 375.09B▲ 24.0% | 52.79B▼ 85.9% | 175.08B▲ 231.7% | 275.88B▲ 57.6% |
Pretax Margin % | 12.27% | 4.52% | -1.85% | 11.45% | 8.48% | 9.31% | 1.24% | 3.82% | 5.77% |
Income Tax | 30.5B | -14.12B | -105.04B | -9.94B | 72.41B | 58.05B | -91.41B | 66.94B | 72.27B |
Effective Tax Rate % | 14.04% | -14.88% | 172.9% | -2.71% | 23.93% | 15.48% | -173.15% | 38.23% | 26.2% |
Net Income | 186.89B▲ 0% | 109.13B▼ 41.6% | 44.24B▼ 59.5% | 376B▲ 749.9% | 230.06B▼ 38.8% | 317.02B▲ 37.8% | 144.07B▼ 54.6% | 107.93B▼ 25.1% | 203.33B▲ 88.4% |
Net Margin % | 10.56% | 5.2% | 1.34% | 11.76% | 6.45% | 7.87% | 3.38% | 2.36% | 4.26% |
Net Income Growth % | 62.59% | -41.61% | -59.46% | 749.9% | -38.81% | 37.8% | -54.56% | -25.08% | 88.39% |
Net Income (Continuing) | 186.71B | 135.08B | 44.29B | 376.17B | 230.17B | 317.04B | 144.2B | 108.14B | 203.61B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 19.98B | 4.01B | 4B | 4.14B | 504M | 549M | 741M | 895M | 1.21B |
EPS (Diluted) | 118.78▲ 0% | 34.78▼ 70.7% | 14.13▼ 59.4% | 119.48▲ 745.6% | 72.94▼ 39.0% | 100.97▲ 38.4% | 45.58▼ 54.9% | 33.62▼ 26.2% | 63.91▲ 90.1% |
EPS Growth % | 62.42% | -70.72% | -59.37% | 745.58% | -38.95% | 38.43% | -54.86% | -26.24% | 90.1% |
EPS (Basic) | 119.68 | 34.78 | 14.21 | 120.36 | 73.57 | 102.15 | 46.05 | 34.17 | 63.91 |
Diluted Shares Outstanding | 1.57B | 1.93B | 3.13B | 3.15B | 3.15B | 3.14B | 3.16B | 3.21B | 3.21B |
Basic Shares Outstanding | 1.56B | 1.92B | 3.11B | 3.12B | 3.13B | 3.1B | 3.13B | 3.21B | 3.15B |
Dividend Payout Ratio | 75.92% | 131% | 638.73% | 75.36% | 123.3% | 88.14% | 199.34% | 280.28% | 162.65% |
TAK Balance Sheet
Takeda Pharmaceutical Company Limited (TAK) balance sheet — assets, liabilities & shareholders' equity
| Metric | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 1.08T | 3.05T | 2.47T | 2.71T | 2.59T | 2.4T | 2.56T | 2.52T | 3.1T |
Cash & Short-Term Investments | 375.17B | 725.37B | 653.44B | 1T | 875B | 553.7B | 472.89B | 405.59B | 597.63B |
Cash Only | 294.52B | 702.09B | 637.61B | 966.22B | 849.7B | 533.53B | 457.8B | 385.11B | 597.63B |
Short-Term Investments | 80.65B | 23.28B | 15.82B | 36.6B | 25.3B | 20.17B | 15.09B | 20.48B | 0 |
Accounts Receivable | 428.79B | 749.12B | 784.92B | 812.71B | 724.38B | 681.69B | 697.61B | 725.25B | 880.15B |
Days Sales Outstanding | 88.4 | 130.38 | 87.05 | 92.76 | 74.08 | 61.78 | 59.72 | 57.78 | 67.24 |
Inventory | 212.94B | 986.74B | 759.6B | 753.88B | 853.17B | 986.46B | 1.21T | 1.22T | 1.4T |
Days Inventory Outstanding | 156.73 | 545.96 | 254.42 | 276.74 | 281.35 | 289.42 | 308.49 | 281.18 | 218.97 |
Other Current Assets | 61.9B | 598.88B | 271.48B | 143.48B | 141.1B | 176.1B | 178.21B | 173B | 223.45B |
Total Non-Current Assets | 3.03T | 10.8T | 10.35T | 10.2T | 10.58T | 11.56T | 12.55T | 11.73T | 12.42T |
Property, Plant & Equipment | 536.8B | 1.32T | 1.39T | 1.45T | 1.58T | 1.69T | 1.99T | 1.97T | 2.13T |
Fixed Asset Turnover | 3.30x | 1.59x | 2.37x | 2.20x | 2.25x | 2.38x | 2.14x | 2.33x | 2.24x |
Goodwill | 1.03T | 4.16T | 4.01T | 4.03T | 4.41T | 4.79T | 5.41T | 5.32T | 5.83T |
Intangible Assets | 1.01T | 4.86T | 4.17T | 3.91T | 3.82T | 4.27T | 4.27T | 3.63T | 3.43T |
Long-Term Investments | 304.38B | 306.9B | 369.45B | 348.35B | 330.13B | 378.86B | 430.61B | 361.93B | 450.68B |
Other Non-Current Assets | 77.98B | 87.47B | 103.85B | 100.34B | 82.61B | 63.33B | 51.21B | 70.28B | 77.34B |
Total Assets | 4.11T▲ 0% | 13.87T▲ 237.8% | 12.82T▼ 7.6% | 12.91T▲ 0.7% | 13.18T▲ 2.1% | 13.96T▲ 5.9% | 15.11T▲ 8.2% | 14.25T▼ 5.7% | 15.52T▲ 8.9% |
Asset Turnover | 0.43x | 0.15x | 0.26x | 0.25x | 0.27x | 0.29x | 0.28x | 0.32x | 0.31x |
Asset Growth % | -5.72% | 237.82% | -7.58% | 0.71% | 2.06% | 5.92% | 8.25% | -5.7% | 8.93% |
Total Current Liabilities | 737.51B | 2.51T | 2.18T | 1.77T | 2.15T | 2.48T | 2.31T | 2.51T | 2.44T |
Accounts Payable | 133.71B | 212.35B | 211.63B | 232.1B | 295.93B | 307.45B | 319.95B | 308.45B | 493.48B |
Days Payables Outstanding | 98.41 | 117.49 | 70.88 | 85.2 | 97.59 | 90.2 | 81.58 | 71.25 | 77.04 |
Short-Term Debt | 18M | 984.95B | 586.82B | 22.15B | 203.99B | 339.6B | 367.25B | 548.94B | 514.38B |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 429.54B | 1.09T | 1.09T | 1.26T | 1.22T | 1.26T | 1.29T | 1.35T | 1.33T |
Current Ratio | 1.46x | 1.21x | 1.13x | 1.53x | 1.21x | 0.97x | 1.11x | 1.01x | 1.27x |
Quick Ratio | 1.17x | 0.82x | 0.79x | 1.10x | 0.81x | 0.57x | 0.58x | 0.52x | 0.70x |
Cash Conversion Cycle | 146.72 | 558.84 | 270.58 | 284.3 | 257.84 | 260.99 | 286.63 | 267.72 | 209.18 |
Total Non-Current Liabilities | 1.35T | 6.2T | 5.92T | 5.96T | 5.35T | 5.12T | 5.52T | 4.81T | 5.27T |
Long-Term Debt | 985.64B | 4.77T | 4.51T | 4.61T | 4.14T | 4.04T | 4.48T | 3.97T | 4.39T |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Tax Liabilities | 90.72B | 721.46B | 710.15B | 542.85B | 451.51B | 270.62B | 113.78B | 35.15B | 26.92B |
Other Non-Current Liabilities | 275.18B | 566.27B | 701.08B | 805.87B | 755.84B | 807.78B | 931.41B | 804.37B | 856B |
Total Liabilities | 2.09T | 8.71T | 8.09T | 7.74T | 7.49T | 7.6T | 7.83T | 7.31T | 7.71T |
Total Debt | 985.66B | 5.75T | 5.09T | 4.64T | 4.35T | 4.38T | 4.84T | 4.52T | 4.9T |
Net Debt | 691.14B | 5.05T | 4.46T | 3.67T | 3.5T | 3.85T | 4.39T | 4.13T | 4.31T |
Debt / Equity | 0.49x | 1.11x | 1.08x | 0.90x | 0.76x | 0.69x | 0.67x | 0.65x | 0.63x |
Debt / EBITDA | 2.33x | 12.70x | 7.45x | 4.34x | 4.16x | 3.79x | 5.64x | 4.09x | 3.67x |
Net Debt / EBITDA | 1.63x | 11.15x | 6.51x | 3.43x | 3.35x | 3.33x | 5.11x | 3.74x | 3.22x |
Interest Coverage | 7.12x | 3.65x | 60.51x | 3.24x | 4.90x | 5.30x | 470.12x | 3.27x | 1.51x |
Total Equity | 2.02T▲ 0% | 5.16T▲ 156.0% | 4.73T▼ 8.4% | 5.18T▲ 9.5% | 5.68T▲ 9.8% | 6.35T▲ 11.8% | 7.27T▲ 14.5% | 6.94T▼ 4.6% | 7.81T▲ 12.6% |
Equity Growth % | 3.51% | 155.95% | -8.45% | 9.51% | 9.78% | 11.81% | 14.47% | -4.65% | 12.58% |
Book Value per Share | 1282.19 | 2670.19 | 1509.22 | 1645.08 | 1801.81 | 2023.95 | 2301.40 | 2160.26 | 2435.93 |
Total Shareholders' Equity | 2T | 5.16T | 4.72T | 5.17T | 5.68T | 6.35T | 7.27T | 6.94T | 7.81T |
Common Stock | 168.65B | 1.64T | 1.67T | 1.67T | 1.68T | 1.68T | 1.68T | 1.69T | 1.7T |
Retained Earnings | 1.56T | 1.57T | 1.37T | 1.51T | 1.48T | 1.54T | 1.39T | 1.19T | 1.06T |
Treasury Stock | -74.37B | -57.14B | -87.46B | -59.55B | -116.01B | -100.32B | -51.26B | -74.81B | -49.34B |
Accumulated OCI | -4.79B | 349.88B | 92.56B | 366.11B | 934.17B | 1.51T | 2.51T | 2.35T | 3.31T |
Minority Interest | 19.98B | 4.01B | 4B | 4.14B | 504M | 549M | 741M | 895M | 1.21B |
TAK Cash Flow Statement
Takeda Pharmaceutical Company Limited (TAK) cash flow — operating, investing & free cash flow history
| Metric | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 377.85B | 328.48B | 669.75B | 1.01T | 1.12T | 977.16B | 716.34B | 1.06T | 995.32B |
Operating CF Margin % | 21.34% | 15.66% | 20.35% | 31.61% | 31.47% | 24.26% | 16.8% | 23.07% | 20.83% |
Operating CF Growth % | 44.57% | -13.07% | 103.89% | 50.94% | 11.1% | -13% | -26.69% | 47.58% | -5.85% |
Net Income | 186.71B | 109.01B | 44.29B | 376.17B | 230.17B | 317.04B | 144.07B | 107.93B | 203.33B |
Depreciation & Amortization | 182.13B | 272.45B | 583.65B | 559.67B | 583.15B | 664.4B | 728B | 761.4B | 764.62B |
Stock-Based Compensation | 18.61B | 20.08B | 29.12B | 37.66B | 43.37B | 60.67B | 70.87B | 72.87B | 0 |
Deferred Taxes | 30.5B | -14.12B | -105.04B | -9.94B | 72.41B | 58.05B | -91.41B | 0 | 0 |
Other Non-Cash Items | -53.49B | -134.89B | 23.06B | -228.42B | 95.4B | -97.74B | 120.81B | 167.25B | 292.37B |
Working Capital Changes | 13.4B | 75.95B | 94.67B | 275.78B | 98.61B | -25.26B | -256B | -52.25B | -264.99B |
Change in Receivables | -647M | -13.38B | -34.83B | -9.32B | 127.29B | 75.13B | 15.1B | -58.96B | -74.4B |
Change in Inventory | 13.72B | 58.68B | 137.49B | 25.98B | -46.15B | -79.16B | -115.74B | -34.97B | -64.99B |
Change in Payables | 6.86B | -16.41B | -29.93B | 210.02B | 75.55B | -53.13B | -9.89B | 0 | -3.34B |
Cash from Investing | -93.34B | -2.84T | 292.12B | 393.53B | -198.13B | -607.1B | -463.86B | -367.06B | -411.19B |
Capital Expenditures | -128.26B | -134.11B | -217.71B | -236.47B | -186.04B | -633.69B | -175.42B | -200.79B | -435.72B |
CapEx % of Revenue | 7.24% | 6.39% | 6.61% | 7.39% | 5.21% | 15.73% | 4.11% | 4.38% | 9.12% |
Acquisitions | 56.75B | -2.87T | 456.66B | 530.39B | -21.48B | 7.96B | -4.74B | 0 | 42.18B |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 26.08B | 124.03B | 11.32B | 37.6B | 808M | 6.53B | -251.66B | -166.26B | -8.52B |
Cash from Financing | -326.23B | 2.95T | -1.01T | -1.09T | -1.07T | -709.15B | -354.42B | -751.42B | -398.08B |
Debt Issued (Net) | -153.14B | 3.16T | -586.09B | -511.46B | -600.48B | -285.07B | 1.51B | -314.31B | 46.49B |
Equity Issued (Net) | -18.76B | -1.17B | -3.74B | -2.14B | -77.53B | -26.93B | -2.33B | -51.86B | -54.72B |
Dividends Paid | -141.89B | -142.95B | -282.58B | -283.36B | -283.67B | -279.42B | -287.19B | -302.5B | -330.71B |
Share Repurchases | -18.76B | -1.17B | -3.74B | -2.14B | -77.53B | -26.93B | -2.33B | -51.86B | -54.72B |
Other Financing | -12.44B | -71.14B | -132.8B | -291.39B | -108.59B | -117.73B | -66.42B | -82.75B | -59.15B |
Net Change in Cash | -46.73B▲ 0% | 407.12B▲ 971.2% | -65.11B▼ 116.0% | 328.61B▲ 604.7% | -116.53B▼ 135.5% | -316.17B▼ 171.3% | -75.73B▲ 76.0% | -72.69B▲ 4.0% | 347.89B▲ 578.6% |
Free Cash Flow | 249.59B▲ 0% | 194.37B▼ 22.1% | 452.04B▲ 132.6% | 774.46B▲ 71.3% | 937.07B▲ 21.0% | 343.47B▼ 63.3% | 235.61B▼ 31.4% | 856.39B▲ 263.5% | 808.7B▼ 5.6% |
FCF Margin % | 14.1% | 9.27% | 13.73% | 24.22% | 26.26% | 8.53% | 5.53% | 18.69% | 16.93% |
FCF Growth % | 67.13% | -22.13% | 132.57% | 71.33% | 21% | -63.35% | -31.4% | 263.47% | -5.57% |
FCF per Share | 158.63 | 100.51 | 144.31 | 246.09 | 297.07 | 109.39 | 74.55 | 266.73 | 252.28 |
FCF Conversion (FCF/Net Income) | 2.02x | 3.01x | 15.14x | 2.69x | 4.88x | 3.08x | 4.97x | 9.80x | 4.90x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 112.98B | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
TAK Key Ratios
Takeda Pharmaceutical Company Limited (TAK) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 5.8% | 9.42% | 3.04% | 0.89% | 7.59% | 4.24% | 5.27% | 2.11% | 1.52% | 2.76% |
Return on Invested Capital (ROIC) | 4.58% | 6.61% | 2.38% | 0.78% | 4.24% | 3.83% | 3.8% | 1.47% | 2.26% | 3.71% |
Gross Margin | 67.74% | 71.99% | 68.54% | 66.89% | 68.91% | 68.99% | 69.11% | 66.43% | 65.51% | 51.06% |
Net Margin | 6.64% | 10.56% | 5.2% | 1.34% | 11.76% | 6.45% | 7.87% | 3.38% | 2.36% | 4.26% |
Debt / Equity | 0.59x | 0.49x | 1.11x | 1.08x | 0.90x | 0.76x | 0.69x | 0.67x | 0.65x | 0.63x |
Interest Coverage | 6.49x | 7.12x | 3.65x | 60.51x | 3.24x | 4.90x | 5.30x | 470.12x | 3.27x | 1.51x |
FCF Conversion | 2.27x | 2.02x | 3.01x | 15.14x | 2.69x | 4.88x | 3.08x | 4.97x | 9.80x | 4.90x |
Revenue Growth | -4.17% | 2.22% | 18.45% | 56.93% | -2.84% | 11.61% | 12.85% | 5.87% | 7.45% | 4.28% |
Related:TAK Dividend History·TAK Revenue History·TAK Price History·TAK P/E History·TAK Financial Ratios·TAK Institutional Holders
TAK Frequently Asked Questions
Takeda Pharmaceutical Company Limited (TAK) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Takeda Pharmaceutical Company Limited (TAK) reported $4.55T in revenue for fiscal year 2025. This represents a 372% increase from $963.48B in 2000.
Takeda Pharmaceutical Company Limited (TAK) grew revenue by 4.3% over the past year. Growth has been modest.
Yes, Takeda Pharmaceutical Company Limited (TAK) is profitable, generating $193.19B in net income for fiscal year 2025 (4.3% net margin).
Dividend & Returns
Yes, Takeda Pharmaceutical Company Limited (TAK) pays a dividend with a yield of 4.11%. This makes it attractive for income-focused investors.
Takeda Pharmaceutical Company Limited (TAK) has a return on equity (ROE) of 2.8%. This is below average, suggesting room for improvement.
Takeda Pharmaceutical Company Limited (TAK) generated $757.21B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.